Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented by Drug (Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and Others), and by Geography

Market Snapshot

dipeptide peptidase 4 inhibitors market
Study Period:

2018 - 2026

Base Year:

2020

Fastest Growing Market:

Latin America

Largest Market:

North America

CAGR:

0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018, and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.

  • Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.
  • Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.

Scope of the Report

The DPP-4 inhibitors market is segmented by brands, and covers the following brands: Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented into five regions: North America, Asia-Pacific, Middle East & Africa, Latin America, and Europe.

By Drug Sitagliptin Januvia
Saxagliptin Onglyza/Kombiglyze
Linagliptin Trajenta
Alogliptin Nesina 
Vildagliptin Galvus
Others Other DPP-4
By Region North America

United States
Canada
Rest of North America

Europe

United Kingdom
Germany
France
Russia
Spain
Italy
Rest of Europe

Asia-Pacific

Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

Middle East & Africa

Saudi Arabia
South Africa
Iran
Egypt
Oman
Rest of Middle East & Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Tradjenta Market will Surpass Merck's Januvia During the Forecast Period

The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market.

dipeptide peptidase 4 inhibitors market

To understand key trends, Download Sample Report

North America Holds the Highest Market Share

  • North America holds 38% of the market share in the global DPP-4 market, followed by the Asia Pacific. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
  • Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.
dipeptide peptidase 4 inhibitors market

To understand geography trends, Download Sample Report

Competitive Landscape

Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position till 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

        1. 5.1.1.1 Januvia (Sitagliptin)

        2. 5.1.1.2 Onglyza (Saxagliptin)

        3. 5.1.1.3 Tradjenta (Linagliptin)

        4. 5.1.1.4 Vipidia/Nesina (Alogliptin)

        5. 5.1.1.5 Galvus (Vildagliptin)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2012-2024)

          1. 5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.1.2 Canada (Value and Volume, 2012-2024)

          1. 5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2024)

          1. 5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2012-2024)

          1. 5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.2.2 Germany (Value and Volume, 2012-2024)

          1. 5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.2.3 Italy (Value and Volume, 2012-2024)

          1. 5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.2.4 Spain (Value and Volume, 2012-2024)

          1. 5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2024)

          1. 5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.2.6 Russia (Value and Volume, 2012-2024)

          1. 5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)

          1. 5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2012-2024)

          1. 5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.3.2 Brazil (Value and Volume, 2012-2024)

          1. 5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)

          1. 5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2012-2024)

          1. 5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.4.2 South Korea (Value and Volume, 2012-2024)

          1. 5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.4.3 China (Value and Volume, 2012-2024)

          1. 5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.4.4 India (Value and Volume, 2012-2024)

          1. 5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.4.5 Australia (Value and Volume, 2012-2024)

          1. 5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.4.6 Vietnam (Value and Volume, 2012-2024)

          1. 5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        7. 5.2.4.7 Malaysia (Value and Volume, 2012-2024)

          1. 5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        8. 5.2.4.8 Indonesia (Value and Volume, 2012-2024)

          1. 5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        9. 5.2.4.9 Philippines (Value and Volume, 2012-2024)

          1. 5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        10. 5.2.4.10 Thailand (Value and Volume, 2012-2024)

          1. 5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)

          1. 5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      5. 5.2.5 Middle East & Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)

          1. 5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.5.2 Iran (Value and Volume, 2012-2024)

          1. 5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.5.3 Egypt (Value and Volume, 2012-2024)

          1. 5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.5.4 Oman (Value and Volume, 2012-2024)

          1. 5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.5.5 South Africa (Value and Volume, 2012-2024)

          1. 5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)

          1. 5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012-2024)

    2. 6.2 Type-2 Diabetes Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Merck And Co.

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Recent Development

      2. 7.1.2 AstraZeneca

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Recent Development

      3. 7.1.3 Bristol Myers Squibb

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Recent Development

      4. 7.1.4 Novartis

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Recent Development

      5. 7.1.5 Takeda Pharmaceuticals

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Recent Development

      6. 7.1.6 Eli Lilly

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Recent Development

      7. 7.1.7 Boehringer Ingelheim

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Development

    2. *List Not Exhaustive
    3. 7.2 Company Share Analysis

      1. 7.2.1 Merck And Co.

      2. 7.2.2 AstraZeneca

      3. 7.2.3 Takeda Pharmaceuticals

      4. 7.2.4 Novartis

      5. 7.2.5 Eli Lilly & Boehringer Ingelheim

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market market is studied from 2018 - 2026.

The Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market is growing at a CAGR of 0% over the next 5 years.

Latin America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • Merck
  • AstraZeneca
  • Eli Lilly

Are the major companies operating in Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!